Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 18/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23384213 | 1.00 | LPAR1 (0.46) | LPAR1LPAR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL24815169 | 0.87 | LPAR1 (0.46) | LPAR1LPAR3 | |
| SCHEMBL29991421 | 0.87 | LPAR1 (0.46) | LPAR1LPAR3 | |
| SCHEMBL29948360 | 0.85 | LPAR1 (0.62) | LPAR1LPAR3 | |
| SCHEMBL23384065 | 0.85 | LPAR1 (0.62) | LPAR1LPAR3 | |
| SCHEMBL24868048 | 0.84 | LPAR1 (0.51) | LPAR1LPAR3 | |
| SCHEMBL30192247 | 0.84 | LPAR1 (0.51) | LPAR1LPAR3 | |
| SCHEMBL24867677 | 0.82 | LPAR1 (0.43) | LPAR1LPAR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL24867635 | 0.82 | LPAR1 (0.49) | LPAR1LPAR3 | |
| SCHEMBL24867624 | 0.82 | LPAR1 (0.49) | LPAR1LPAR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503454-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-10-02 | — | — | US | disclosed |
| CN-119330971-A | Compounds used as CDK7 kinase inhibitor and application thereof | 深圳艾克斯恩生物科技有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-12139474-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4337654-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240002367-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-04 | — | — | US | disclosed |
| US-11702407-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| EP-4161641-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-4161936-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11584738-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220411406-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2022241023-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| EP-4058144-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702407-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885ALDH1A1 1727/4885 |
| US-11584738-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885ALDH1A1 1726/4885 |
| US-12139474-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885ALDH1A1 1743/4885 |
| US-20220411406-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885ALDH1A1 1726/4885 |
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | LPAR1 2/4885LPAR3 1/4885ALDH1A1 2326/4885 |
| US-11999717-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | LPAR1 2/4885LPAR3 1/4885ALDH1A1 2326/4885 |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | LPAR1 2/4885LPAR3 1/4885ALDH1A1 2326/4885 |
| US-12503454-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885ALDH1A1 1726/4885 |
| US-20240002367-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885ALDH1A1 1743/4885 |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885ALDH1A1 1726/4885 |
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885ALDH1A1 1726/4885 |
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885ALDH1A1 1726/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 4/4885ALDH1A1 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.